Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635169 | 1.00 | LMNA (0.39) | LMNAL3MBTL1MPITDP1USP2 | |
| SCHEMBL10713437 | 1.00 | LMNA (0.39) | LMNAL3MBTL1MPITDP1USP2 | |
| SCHEMBL8836136 | 0.88 | AKR1B1 (0.37) | LMNAL3MBTL1MPIAKR1B1 | |
| SCHEMBL1764018 | 0.84 | AKR1B1 (0.34) | LMNAL3MBTL1MPITDP1USP2 | |
| SCHEMBL2635114 | 0.84 | AKR1B1 (0.34) | LMNAL3MBTL1MPITDP1USP2 | |
| SCHEMBL4288124 | 0.84 | AKR1B1 (0.34) | LMNAL3MBTL1MPITDP1USP2 | |
| SCHEMBL1267825 | 0.82 | LMNA (0.37) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2115466 | 0.82 | LMNA (0.37) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8970781 | 0.80 | LMNA (0.39) | LMNAL3MBTL1MPITDP1USP2 | |
| SCHEMBL309709 | 0.80 | LMNA (0.39) | LMNAL3MBTL1MPITDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200026-B2 | Antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | claimed |
| US-4169197-A | ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1979-09-25 | — | — | US | claimed |
| CN-118897028-B | Biomarker for predicting gout attack risk and application thereof | 查理高特(青岛)健康科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-118897028-A | Biomarker for predicting gout attack risk and application thereof | 查理高特(青岛)健康科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20210070797-A1 | PROCESSES FOR PREPARING FLUOROKETOLIDES | Têtard, Inc. (US) | 2021-03-11 | — | — | US | disclosed |
| EP-3738591-A2 | NOVEL ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-2968801-B1 | METHODS FOR TREATING RESPIRATORY DISEASES AND FORMULATIONS THEREFOR | CEMPRA PHARMACEUTICALS INC (US) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018045294-A1 | PROCESSES FOR PREPARING FLUOROKETOLIDES | CEMPRA PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180044365-A1 | PROCESSES FOR PREPARING FLUOROKETOLIDES | TETARD, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3265100-A1 | PROCESSES FOR PREPARING FLUOROKETOLIDES | Cempra Pharmaceuticals Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9861616-B2 | Methods for treating respiratory diseases and formulations therefor | CEMPRA PHARMACEUTICALS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20120071429-A1 | Novel antibacterial agents | TETARD, INC. | 2012-03-22 | — | — | US | disclosed |
| US-8012943-B2 | Antibacterial agents | OPTIMER PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7601695-B2 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | OPTIMER PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090209593-A1 | NOVEL ANTIBACTERIAL AGENTS | TETARD, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20060100164-A1 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | TETARD, INC. | 2006-05-11 | — | — | US | disclosed |
| EP-1638549-A2 | NOVEL ANTIBACTERIAL AGENTS | Optimer Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004080391-A2 | NOVEL ANTIBACTERIAL AGENTS | OPTIMER PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-4048430-A | Mercaptopseudotrisaccharides | SMITHKLINE CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-3960838-A | Mercaptopseudodisaccharides | SMITHKLINE CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044365-A1 | PROCESSES FOR PREPARING FLUOROKETOLIDES | FDPS, PFAS, PFKFB3 | LMNA 355/4885L3MBTL1 4310/4885MPI 55/4885 |
| US-20120071429-A1 | Novel antibacterial agents | MRPL21, CTSA, MRPL12 | LMNA 2774/4885L3MBTL1 2037/4885MPI 1693/4885 |
| US-20060100164-A1 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | MLNR, RPL13A, PGC | LMNA 1871/4885L3MBTL1 773/4885MPI 180/4885 |
| US-20210070797-A1 | PROCESSES FOR PREPARING FLUOROKETOLIDES | FDPS, PFAS, PFKFB3 | LMNA 355/4885L3MBTL1 4310/4885MPI 55/4885 |
| US-20090209593-A1 | NOVEL ANTIBACTERIAL AGENTS | MRPL21, MRPL12, CTSA | LMNA 2861/4885L3MBTL1 2070/4885MPI 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.